Rush health system CEO to step down in 2027
The system said a longer transition before Dr. Omar Lateef’s departure will ensure stability as it searches for a new leader.
Uncategorized
ACA enrollment declines by nearly 3M
ACA plan enrollment continues to shrink following the lapse of more generous subsidies last year, according to new federal data.
Por qué un divorcio de mutuo acuerdo reduce el daño psicológico en adultos e hijos
Investigaciones previas publicadas en revistas especializadas como Personality and Social Psychology Bulletin ya habían documentado que el divorcio de los padres genera vínculos de apego más inseguros en los hijos, especialmente cuando la ruptura se produce antes de los cinco a& …
Por qué un divorcio de mutuo acuerdo reduce el daño psicológico en adultos e hijos Read More »
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.
HHS details takeaways from sweeping AI request for information
The healthcare sector wants the HHS to coordinate its AI strategy across agencies, provide implementation and governance support, and offer help in evaluating AI tools, leaders said Thursday.
HHS details takeaways from sweeping AI request for information Read More »
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
Zymeworks announced a new plan to become a royalty-driven company last year, making Theravance a perfect match.
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance Read More »
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout
The star of Ipsen’s acquisition is an MDM2 blocker being proposed as an add-on therapy to ruxolitinib for myelofibrosis. The drug could be available to patients “as early as 2028,” according to Ipsen CEO David Loew.
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout Read More »
Viridian debuts on market with FDA greenlight for thyroid eye disease drug
Viridian Therapeutics’ Lumvoa is the first FDA-approved treatment for thyroid eye disease that includes data for both active and chronic forms of the illness.
Viridian debuts on market with FDA greenlight for thyroid eye disease drug Read More »
¿Confiamos demasiado en la inteligencia artificial?
La rápida aparición de la inteligencia artificial generativa en la educación superior ha suscitado preocupación por la dependencia que los estudiantes pueden desarrollar hacia esta herramienta a la hora de realizar tareas académicas. Aunque la IA generativa puede m …
¿Confiamos demasiado en la inteligencia artificial? Read More »
Alteraciones neuroinmunitarias y fibromialgia
La fibromialgia es un trastorno complejo caracterizado principalmente por dolor crónico generalizado, fatiga y otros síntomas físicos y cognitivos. Aunque afecta a millones de personas en todo el mundo, todavía no se conocen del todo los mecanismos biológicos que h …